Sponsors / CPIX
CPIX

Cumberland Pharmaceuticals

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
12Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionNCT02682511Cumberland PharmaceuticalsPhase 2Active not recruiting2026-03Actual
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)NCT03028350Cumberland PharmaceuticalsPhase 2Completed2023-04-25Actual
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyNCT03340675Cumberland PharmaceuticalsPhase 2Completed2024-03-06Actual
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)NCT05571059Cumberland PharmaceuticalsPhase 2Recruiting2028-01Estimated

Latest recorded trial changes

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675 · Cumberland Pharmaceuticals

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability)

+ After

Measure: Incidence of Treatment-Emergent Adverse Events

Check registry source
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

NCT03340675 · Cumberland Pharmaceuticals

· 5 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment-Emergent Adverse Events (safety & tolerability)

+ After

Measure: Incidence of Treatment-Emergent Adverse Events (Safety & Tolerability)

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

48 participants (planned)

+ After

46 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Sep 2025

+ After

6 Mar 2024

Check registry source